FDA Adds New Warnings to All Testosterone Product Labels

Testosterone and other AAS, which have a schedule III classification by the Controlled Substances Act, may be abused by adults and adolescents, including athletes and body builders.

“Abuse of testosterone, usually at doses higher than those typically prescribed and usually in conjunction with other AAS, is associated with serious safety risks affecting the heart, brain, liver, mental health, and endocrine system,” the FDA notes.

Reported serious adverse outcomes include myocardial infarction, heart failure, stroke, depression, hostility, aggression, liver toxicity, and male infertility. People abusing high doses of testosterone have also reported withdrawal symptoms, such as depression, fatigue, irritability, loss of appetite, decreased libido, and insomnia, the agency says.

Source: FDA Adds New Warnings to All Testosterone Product Labels

Source: Safety Alerts for Human Medical Products > Testosterone and Other Anabolic Androgenic Steroids (AAS): FDA Statement – Risks Associated With Abuse and Dependence

It is interesting you no longer see those Low-T commercials on television any more.  Really?  Just another clever marketing campaign to create a disease that doesn’t exist along with a convenient drug based solution.  What side effects?

Read this book.  Now.

Source: Bill Moyers Journal . Profile . Melody Petersen | PBS

Genworth Sold to China-based Firm – Richmond Times

The top executive at Genworth Financial Inc. assured analysts and investors Monday that the proposed sale to a China-based investment firm was “the best option” to preserve and create value for shareholders.

Genworth, a major seller of home mortgage insurance and long-term care insurance, announced Sunday evening that its board agreed for the Henrico County-based company to be bought for about $2.7 billion by Beijing-based China Oceanwide Holdings Group, a privately held international financial company that has been expanding its holdings in the U.S.

Source: Genworth CEO: selling company to China-based firm is ‘best option’ – Richmond Times-Dispatch: Richmond Area Business News

Diagnosing PE in Pregnant Women — Brown Emergency Medicine

Epidemiology – Venous thromboembolism (VTE) occurs in pregnant women at 7-10 times the incidence in age-matched controls. Pregnant women who get VTE have deep venous thrombosis (DVT) approximately 3 times as often as pulmonary embolism (PE). The increased risk is similar during all three trimesters, starts to diminish after delivery, and returns to baseline by six weeks post-partum. The left leg is affected in 85% of pregnancy-associated DVT, possibly from compression of the left iliac vein. Isolated pelvic DVT is also more common in pregnancy. In the developed world, pregnancy-associated VTE is the leading cause of maternal mortality.

Source: Diagnosing PE in Pregnant Women — Brown Emergency Medicine